299 related articles for article (PubMed ID: 33021056)
1. Role of post-translational modifications in the acquisition of drug resistance in Mycobacterium tuberculosis.
Arora G; Bothra A; Prosser G; Arora K; Sajid A
FEBS J; 2021 Jun; 288(11):3375-3393. PubMed ID: 33021056
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
4. [Post-translational modification and regulatory network of Mycobacterium tuberculosis antibiotic resistance].
Xie L; Dang Y; Xie J
Sheng Wu Gong Cheng Xue Bao; 2018 Aug; 34(8):1279-1287. PubMed ID: 30152213
[TBL] [Abstract][Full Text] [Related]
5. The role of epigenetics, bacterial and host factors in progression of Mycobacterium tuberculosis infection.
Marimani M; Ahmad A; Duse A
Tuberculosis (Edinb); 2018 Dec; 113():200-214. PubMed ID: 30514504
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal whole genome analysis of pre and post drug treatment Mycobacterium tuberculosis isolates reveals progressive steps to drug resistance.
Datta G; Nieto LM; Davidson RM; Mehaffy C; Pederson C; Dobos KM; Strong M
Tuberculosis (Edinb); 2016 May; 98():50-5. PubMed ID: 27156618
[TBL] [Abstract][Full Text] [Related]
7. Mutations of rpoB, katG, inhA and ahp genes in rifampicin and isoniazid-resistant Mycobacterium tuberculosis in Kyrgyz Republic.
Isakova J; Sovkhozova N; Vinnikov D; Goncharova Z; Talaibekova E; Aldasheva N; Aldashev A
BMC Microbiol; 2018 Mar; 18(1):22. PubMed ID: 29566660
[TBL] [Abstract][Full Text] [Related]
8. Variants of katG, inhA and nat genes are not associated with mutations in efflux pump genes (mmpL3 and mmpL7) in isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from India.
Unissa AN; Dusthackeer VNA; Kumar MP; Nagarajan P; Sukumar S; Kumari VI; Lakshmi AR; Hanna LE
Tuberculosis (Edinb); 2017 Dec; 107():144-148. PubMed ID: 29050763
[TBL] [Abstract][Full Text] [Related]
9. Recent updates on drug resistance in Mycobacterium tuberculosis.
Singh R; Dwivedi SP; Gaharwar US; Meena R; Rajamani P; Prasad T
J Appl Microbiol; 2020 Jun; 128(6):1547-1567. PubMed ID: 31595643
[TBL] [Abstract][Full Text] [Related]
10. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.
de Wet TJ; Warner DF; Mizrahi V
Acc Chem Res; 2019 Aug; 52(8):2340-2348. PubMed ID: 31361123
[TBL] [Abstract][Full Text] [Related]
11. Ample glycosylation in membrane and cell envelope proteins may explain the phenotypic diversity and virulence in the Mycobacterium tuberculosis complex.
Birhanu AG; Yimer SA; Kalayou S; Riaz T; Zegeye ED; Holm-Hansen C; Norheim G; Aseffa A; Abebe M; Tønjum T
Sci Rep; 2019 Feb; 9(1):2927. PubMed ID: 30814666
[TBL] [Abstract][Full Text] [Related]
12. GeneChip analysis of resistant Mycobacterium tuberculosis with previously treated tuberculosis in Changchun.
Zhang MJ; Ren WZ; Sun XJ; Liu Y; Liu KW; Ji ZH; Gao W; Yuan B
BMC Infect Dis; 2018 May; 18(1):234. PubMed ID: 29788948
[TBL] [Abstract][Full Text] [Related]
13. Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis.
Unissa AN; Subbian S; Hanna LE; Selvakumar N
Infect Genet Evol; 2016 Nov; 45():474-492. PubMed ID: 27612406
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of novel
Valafar F; Ramirez-Busby SM; Torres J; Paul LV; Rodwell TC; Victor TC; Rodrigues C; Gler MT; Crudu V; Catanzaro T
Int J Mycobacteriol; 2015 Mar; 4(Suppl 1):51-52. PubMed ID: 27695670
[TBL] [Abstract][Full Text] [Related]
15. The role of two-component systems in the physiology of Mycobacterium tuberculosis.
Kundu M
IUBMB Life; 2018 Aug; 70(8):710-717. PubMed ID: 29885211
[TBL] [Abstract][Full Text] [Related]
16. The Mycobacterium tuberculosis Uganda II family and resistance to first-line anti-tuberculosis drugs in Uganda.
Ezati N; Lukoye D; Wampande EM; Musisi K; Kasule GW; Cobelens FG; Kateete DP; Joloba ML
BMC Infect Dis; 2014 Dec; 14():703. PubMed ID: 25523472
[TBL] [Abstract][Full Text] [Related]
17. Toward Understanding the Essence of Post-Translational Modifications for the Mycobacterium tuberculosis Immunoproteome.
van Els CA; Corbière V; Smits K; van Gaans-van den Brink JA; Poelen MC; Mascart F; Meiring HD; Locht C
Front Immunol; 2014; 5():361. PubMed ID: 25157249
[TBL] [Abstract][Full Text] [Related]
18. Lipid transport in Mycobacterium tuberculosis and its implications in virulence and drug development.
Bailo R; Bhatt A; Aínsa JA
Biochem Pharmacol; 2015 Aug; 96(3):159-67. PubMed ID: 25986884
[TBL] [Abstract][Full Text] [Related]
19. Characterization of katG, inhA, rpoB and pncA in Mycobacterium tuberculosis isolates from MDR-TB risk patients in Thailand.
Suthum K; Samosornsuk W; Samosornsuk S
J Infect Dev Ctries; 2020 Mar; 14(3):268-276. PubMed ID: 32235087
[TBL] [Abstract][Full Text] [Related]
20. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
